In a bid to expand its dermatology portfolio, Sun Pharma has agreed to buy Concert Pharmaceuticals under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of US$8 per share of common stock in cash or US$576 M in equity value. With the takeover, Sun Pharma will gain access to Concert’s lead candidate, deuruxolitinib, which is a novel, deuterated, oral JAK1/2 inhibitor currently in Phase III studies for alopecia areata.